Overview

Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)

Status:
Terminated
Trial end date:
2018-02-06
Target enrollment:
Participant gender:
Summary
The goal of the study is to find the best dose of pacritinib when given in combination with erlotinib.
Phase:
Phase 1
Details
Lead Sponsor:
Washington University School of Medicine
Treatments:
Endothelial Growth Factors
Erlotinib Hydrochloride